<DOC>
	<DOCNO>NCT00446342</DOCNO>
	<brief_summary>The purpose study assess safety tolerability escalate dos SNS-032 , give 3 weekly administration per cycle identify recommend Phase 2 dose .</brief_summary>
	<brief_title>Study Intravenously Administered SNS-032 Patients With Advanced B-lymphoid Malignancies</brief_title>
	<detailed_description>Other objective study include measure pharmacokinetics ( long drug measure body ) identify potential biomarkers .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Cyclin-Dependent Kinase Inhibitor Proteins</mesh_term>
	<criteria>Cytologically histologically confirm chronic lymphocytic leukemia ( CLL ) , mantle cell lymphoma ( MCL ) , multiple myeloma ( MM ) . Evidence relapse disease Measurable disease Eastern Cooperative Oncology Group ( ECOG ) Performance Status score 0 1 Prior treatment SNS032 injection ( previously know BMS387032 ) Pregnant breastfeed Unwilling use approve , effective mean contraception accord study site 's standard Use therapeutic anticoagulation agent Prior allogeneic bone marrow transplantation Prior chemotherapy , monoclonal antibody , investigational agent , radiation therapy within 21 day first dose ; nitrosoureas mitomycin permit least 42 day first dose . Prior pelvic radiation therapy radiation &gt; 25 % bone marrow reserve Any medical , psychological , social condition would contraindicate patient 's participation clinical study due safety concern compliance clinical study procedure Please note : There additional inclusion/exclusion criterion study . Please contact study center additional information determine patient meet study criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>leukemia</keyword>
	<keyword>lymphoma</keyword>
	<keyword>myeloma</keyword>
	<keyword>non-Hodgkin 's</keyword>
	<keyword>CLL</keyword>
	<keyword>MCL</keyword>
	<keyword>MM</keyword>
	<keyword>Phase 1</keyword>
	<keyword>hematological malignancy</keyword>
</DOC>